Step 1 · Pharmacology Principles

Drug Development & Clinical Pharmacology

Name: Drug Development & Clinical Pharmacology
Creator: Veli Bakalov, MD

From IND to black box: how a molecule becomes a marketed drug

Pharmacology Principles·Clinical Pharmacology·4 min read·9 high-yield points·Reviewed by Veli Bakalov, MD @HemeOncBuddy

Study materialsNo account needed

Card deckActive-recall cards · quick checks · quiz

High-yield

The IND (filed after preclinical animal data) permits first-in-human testing; the NDA (or BLA for biologics) after Phase III requests marketing approval; the ANDA is the abbreviated route for generics.
Phase I = safety, PK/PD, and maximum tolerated dose in ~20–100 healthy volunteers (patients for chemotherapy and HIV drugs).
Phase II = efficacy, dosing, and adverse effects in ~100–300 patients with the disease; many drugs fail here.
Phase III = pivotal randomized controlled trial in ~300–3,000 patients vs placebo or standard of care; Phase IV = post-marketing surveillance for rare or long-term harms.
Generic bioequivalence: the 90% CI for AUC and Cmax must fall within 80–125% of the brand; no repeat efficacy trials are needed.
Orphan Drug Act (1983): diseases affecting fewer than 200,000 Americans; 7 years of market exclusivity, tax credits, and waived fees.
NNT = 1/ARR (ARR = control event rate − treatment event rate); lower NNT is better, and relative risk reduction can exaggerate benefit.
Boxed warning = the FDA's strongest label alert: antidepressants (suicidality under 25), fluoroquinolones (tendon rupture), antipsychotics (mortality in elderly dementia), thiazolidinediones (heart failure).
Narrow-therapeutic-index drugs need level monitoring: warfarin (INR), digoxin, lithium, aminoglycosides, vancomycin, phenytoin, theophylline, tacrolimus.

The development pipeline

Bench to market. Preclinical in vitro and animal testing, then an IND filing, then Phase I–III human trials, then NDA/BLA approval, then Phase IV surveillance. Only a tiny fraction of candidates survive (roughly 1 in 1,000 preclinical compounds reaches the market), and development takes about 10–15 years.

Investigational New Drug (IND) application. Submitted to the FDA once preclinical animal toxicology and pharmacology data are in hand; it permits the first human testing.

New Drug Application (NDA) / Biologics License Application (BLA). Filed after successful Phase III trials to request marketing approval; the BLA is the equivalent route for biologics. The ANDA is the abbreviated route for generics.

PreclinicalIn vitro and animal pharmacology and toxicology
INDPermits first-in-human testing
Phases I–IIISafety, then efficacy, then the pivotal RCT
NDA / BLAMarketing approval
Phase IVPost-marketing surveillance for life

From molecule to marketed drug

Clinical trial phases

Phase I: is it safe? About 20–100 healthy volunteers; defines safety, pharmacokinetics and pharmacodynamics, and the maximum tolerated dose. Exception: cytotoxic chemotherapy and HIV drugs are tested in patients, because they are too toxic to give healthy people.

Phase II: does it work? About 100–300 patients with the disease; evaluates efficacy, optimal dosing, and adverse effects. Many candidates fail here for lack of efficacy.

Phase III: the pivotal RCT. About 300–3,000 patients in a large randomized, usually double-blinded trial comparing the drug with placebo or the current standard, confirming efficacy and monitoring adverse reactions. Success supports the NDA/BLA. It is the most expensive phase.

Phase IV: rare and late harms. Post-marketing surveillance (pharmacovigilance) after approval detects adverse effects too rare or delayed to appear in pre-approval trials. Spontaneous reports to MedWatch and FAERS can trigger boxed warnings or withdrawal, as with rofecoxib and cerivastatin.

Trial phases at a glance

Phase	Subjects	Approximate size	Main question
I	Healthy volunteers (patients for chemo, HIV drugs)	20–100	Is it safe? PK/PD, maximum tolerated dose
II	Patients with the disease	100–300	Does it work? Dosing, adverse effects
III	Patients, randomized vs placebo or standard	300–3,000	Is it better or equivalent? Pivotal for approval
IV	Everyone prescribed the drug	Post-marketing	Rare or long-term harms

Generics and orphan drugs

Generics and bioequivalence. A generic must contain the same active ingredient, dose, and route and be bioequivalent: the 90% confidence interval for its AUC and Cmax must fall within 80–125% of the brand. It is approved through an ANDA without repeating Phase I–III efficacy trials. Biologics have no true generics; their copies are biosimilars, highly similar but not identical to the reference product.

Orphan drugs. The Orphan Drug Act (1983) covers diseases affecting fewer than 200,000 Americans and offers incentives to develop treatments for them: 7 years of market exclusivity, tax credits for trials, and waived FDA fees.

80–125%Bioequivalence window for AUC and Cmax (90% CI) vs the brand

<200,000US patients for orphan drug eligibility

7 yearsOrphan market exclusivity

Interpreting trial results

Absolute vs relative benefit. Absolute risk reduction (ARR) is the control event rate minus the treatment event rate. Number needed to treat (NNT) = 1/ARR, the number of patients treated to prevent one bad outcome; a lower NNT means a more effective therapy. Number needed to harm (NNH) = 1/attributable risk. Relative risk reduction (RRR) can exaggerate benefit when events are rare: cutting an event rate from 2% to 1% is a 50% RRR but an NNT of 100.

Effect-size measures

Measure	Formula	Worked example (10% → 5%)
ARR	Control rate − treatment rate	0.10 − 0.05 = 0.05
RRR	ARR / control rate	0.05 / 0.10 = 50%
NNT	1 / ARR	1 / 0.05 = 20
NNH	1 / attributable risk	Patients exposed per one extra harm

Placebo and nocebo. The placebo effect is benefit from an inert treatment through positive expectation; the nocebo effect is adverse symptoms from negative expectation (e.g., much reported statin intolerance). Randomization, placebo controls, and blinding separate the true drug effect from expectation.

Safety after approval

Boxed (black box) warning. The FDA's most serious labeling alert, reserved for life-threatening risks. Classics:

Antidepressants: suicidality in patients younger than 25
Fluoroquinolones: tendinitis and tendon rupture (aortic aneurysm and dissection are an added label warning)
Antipsychotics: increased mortality in elderly patients with dementia
Thiazolidinediones: heart failure

Risk management. For some high-risk drugs, the FDA requires a Risk Evaluation and Mitigation Strategy (REMS), such as the isotretinoin pregnancy-prevention program.

Narrow therapeutic index drugs. Therapeutic index = TD50/ED50; a low value means a small margin between effect and toxicity, so levels are monitored: warfarin (INR), digoxin, lithium, aminoglycosides and vancomycin, phenytoin, theophylline, and tacrolimus.

Sequence to remember: IND opens human trials; Phase I tests safety, II efficacy, III the pivotal comparison; the NDA/BLA opens the market; Phase IV keeps watching.